In addition to the relapsed IDH1-mutated AML population, the United States Food and Drug Administration (FDA) has approved ivosidenib as monotherapy for the newly diagnosed older and chemotherapy-ineligible population based on these results. Here, IDH1 is linked to acute myeloid leukemia.